Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0IX1I
|
||||
| Former ID |
DIB003664
|
||||
| Drug Name |
NBI-98854
|
||||
| Synonyms |
NBI-98782; Vesicular monoamine transporter 2 inhibitor (CNS indications), Neurocrine; VMAT-2 inhibitor (CNS disease), Neurocrine
|
||||
| Drug Type |
Small molecular drug
|
||||
| Company |
Neurocrine biosciences
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C24H38N2O4
|
||||
| InChI |
InChI=1S/C24H38N2O4/c1-14(2)9-17-13-26-8-7-16-10-21(28-5)22(29-6)11-18(16)19(26)12-20(17)30-24(27)23(25)15(3)4/h10-11,14-15,17,19-20,23H,7-9,12-13,25H2,1-6H3/t17-,19-,20-,23+/m1/s1
|
||||
| InChIKey |
GEJDGVNQKABXKG-CFKGEZKQSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Synaptic vesicle amine transporter | Target Info | Inhibitor | [533314] | |
| PANTHER Pathway | Adrenaline and noradrenaline biosynthesis | ||||
| 5HT1 type receptor mediated signaling pathway | |||||
| 5HT2 type receptor mediated signaling pathway | |||||
| 5HT3 type receptor mediated signaling pathway | |||||
| 5HT4 type receptor mediated signaling pathway | |||||
| Dopamine receptor mediated signaling pathway | |||||
| Nicotine pharmacodynamics pathway | |||||
| CCKR signaling map ST | |||||
| References | |||||
| Ref 524967 | ClinicalTrials.gov (NCT02274558) A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia. U.S. National Institutes of Health. | ||||
| Ref 543251 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8694). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.